Drugs / L-glutamine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | NUTRESTORE | — | 2004-06-10 | fda.gov ↗ |
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04019769 | Mar 2020 → Jan 2021 | atopic eczema | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 13 trials | ||||||
| Phase 1 | NCT04634539 | May 2021 → Jul 2023 | pancreatic ductal adenocarcinoma | Jun Gong, MD | Completed | No outcome recorded |
| Phase 1 | NCT05106101 | Jul 2019 → Dec 2022 | large intestine disorder | Emmaus Medical, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03947879 | May 2019 → May 2021 | type 2 diabetes mellitus | Hawaii Pacific Health | Unknown | No outcome recorded |
| Phase 26 trials · 2 missed | ||||||
| Phase 2 | NCT06967428 | Sep 2025 → Jan 2026 overdue | — | Independent Medical Alliance | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04274114 | Jan 2019 → May 2020 | generalized anxiety disorder | Hospital Universitario Dr. Jose E. Gonzalez | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01048905 | Mar 2009 → Mar 2014 | pulmonary hypertension, sickle cell disease, thalassemia | UCSF Benioff Children's Hospital Oakland | Completed | No outcome recorded |
| Phase 2 | NCT00296621 | Feb 2006 → Feb 2008 | Duchenne muscular dystrophy | Assistance Publique - Hôpitaux de Paris | Completed | Missed primary |
| Phase 2 | NCT00125788 | Mar 2004 → Jul 2008 | sickle cell disease, thalassemia | Emmaus Medical, Inc. | Completed | Missed primary |
| Phase 2 | NCT00586209 | Feb 2004 → Aug 2008 | sickle cell disease, thalassemia | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Terminated | No outcome recorded Stop: Business |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07210450 | Aug 2023 → May 2025 | thalassemia | Mazandaran University of Medical Sciences | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT01179217 | May 2010 → Mar 2014 | sickle cell disease, sickle cell-beta zero-thalassemia | Emmaus Medical, Inc. | Completed | Met primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT05371184 | Jan 2022 → Jan 2023 | sickle cell disease | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT04684381 | Jan → Jun 2021 | sickle cell disease | Emmaus Medical, Inc. | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05808010 | Jun 2023 → Apr 2025 | chronic atrophic gastritis | Shandong Provincial Hospital | Unknown | No outcome recorded |
| — | NCT04701463 | Jan → Nov 2020 | obesity disorder, skin disorder | Azienda di Servizi alla Persona di Pavia | Completed | No outcome recorded |
Press releases naming this drug 17 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-Glutamine | “This daily intervention over 3 months combines 4 g L-serine, 14 g L-glutamine, 3 g L-arginine, 2.5 g N-acetylcysteine, 5.75 g L-citrulline, 1 g vitamin C, and 5 g creatine to...” NCT06967428 ↗15“L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate” NCT04701463 ↗ |
| Known as | glutamine | “Oral therapy with pharmaceutical-grade l-glutamine (USAN, glutamine) has been shown to increase the proportion of the reduced form of nicotinamide adenine dinucleotides in...” PMID 30021096 ↗ Jul 20181“2 intervention periods: glutamine (0.5 g/kg/d) and placebo, 4 months each” PMID 19421321 ↗ May 2009 |
| Action | Restore | “Glutamine supplementation can normalize this defect in mTORC1.” NCT04019769 ↗ |
| Modality | Other / unclassified | “Glutamine is an amino acid.” NCT04019769 ↗ |
| Route | Oral | “Approximately 0.3 g/kg total daily dose of L-glutamine will be orally administered” NCT00125788 ↗ |